Article Text

Download PDFPDF
Postnatal corticosteroids to treat or to prevent chronic lung disease: a survey of neonatologists’ practices
  1. R Niwas1,
  2. M Kamat1,2,
  3. P Kling1,
  4. T F Yeh1,3,
  5. S Pyati1,2
  1. 1
    Department of Pediatrics, John H Stroger, Jr. Hospital of Cook County, Chicago, Illinois, USA
  2. 2
    Rosalind Franklin University of Medicine and Science, Chicago Medical School, North Chicago, Illinois, USA
  3. 3
    Department of Pediatrics, College of Medicine, China Medical University, Taichung, Taiwan
  1. Ram Niwas, Division of Neonatology, Department of Pediatrics, John H Stroger, Jr. Hospital of Cook County, 1901 W Harrison St, Chicago, Illinois 60612, USA; ram_niwas{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A nationwide decline in postnatal steroid use has possibly occurred pursuant to the 2002 AAP Statement that, “outside the context of a randomized, controlled trial, the use of corticosteroids should be limited to exceptional clinical circumstances (e.g., an infant on maximal ventilatory and oxygen support)”.1 Studies in preterm infants have found that the early beneficial effects of corticosteroids on the pulmonary system are outweighed by an increased risk of adverse effects including impaired growth and neurodevelopmental delay.2 The objective of this study was to determine the …

View Full Text


  • Competing interests: None.